The clinical study on the efficacy and safety of single arm, multicenter to evaluate of the analgesic effect and the safety of Yaotongning capsules treatment on lumbar Discherniation?Lumbar osteoarthritis?Sciatica?lumbar muscle degeneration?Psoas fibrositis?Heumatoid arthritis.

The clinical studies Yaotongning capsules listed after the evaluation

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONC-13003714

Enrollment

Unknown

Registered

2013-10-20

Start date

2013-10-21

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lumbar Discherniation, Lumbar osteoarthritis?Sciatica?lumbar muscle degeneration?Psoas fibrositis?Heumatoid arthritis

Interventions

experimental group:Yaotongning capsules

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Conforms to the diagnosis standard of lumbar Discherniation, Lumbar osteoarthritis, Sciaticalumbar muscle degeneration, Psoas fibrositis, Heumatoid arthritis; 2. Conforms to the TCM syndromes of Cold dampness and blood stasis (western medicine doctor can not discriminate); 3. At least 18 years of age; 4. Subjects agreed, and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women, pregnancy preparation; 2. Allergic constitution(allergic to two or more substances), allergic to this drug composition ingredients and alcohol; 3. These were not enrolled in this study with cardiovascular and cerebrovascular diseases, Lung disease, liver disease, kidney disease, blood disease, metabolic disordersendocrine disorders, infectious diseases seriously, eg. Liver function tests (ALT, AST, T-Bil), Renal function tests (BUN)results exceed the upper limit of 50%, and Creatinine results exceed the upper limit; 4. Epileptic or using other methods of treatment in patients with anti rheumatism with Hypertension(170/100mmHg); 5. Doctors consider that should not be selected.

Design outcomes

Primary

Measure	Time frame
VAS;The onset time on acesodyn;	—

Secondary

Measure	Time frame
Oswestry disability index;	—

Countries

China

Contacts

Public ContactChunmin Wang

The First Affiliated Hospital of TianJin University of Traditionnal Chinese Medicine

13932405279@139.com+86 13603140779

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026